Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
  Current framework programme
  Economic development and cohesion
  Enlargement
  European Research Area
  Past framework programmes
  Regional dimension of innovation
  Scientific support to policies
  Sixth Framework Programme
  Other
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Brazil
  Bulgaria
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Finland
  France
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Ireland
  Israel
  Italy
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lithuania
  Luxembourg
  Malta
  Mexico
  Montenegro
  Morocco
  Namibia
  Netherlands
  Nigeria
  Norway
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tunisia
  Turkey
  Ukraine
  United Kingdom
  United States


This page was published on 01/08/2006
Published: 01/08/2006

   Research policy

Last Update: 01-08-2006  
Related category(ies):
Health & life sciences  |  Research policy

 

Add to PDF "basket"

A case for more public funding for cancer research

A major pan-European survey published in PLoS Medicine has found that there is inadequate public funding of cancer research when set against the actual burden of cancer in Europe, and compared with the United States.

Comparison of direct cancer research expenditure between EU-15 only (left) and the USA (right) as percentage of GDP.Source: PLoS
Comparison of direct cancer research expenditure between EU-15 only (left) and the USA (right) as percentage of GDP.
Source: PLoS
The European Cancer Research Funding Survey found that, across the EU, the average public spending on cancer research was €2.56 (US$3.30) per person, compared with €17.63 (US$22.76) per person in the United States. As a percentage of GDP, the USA paid four times more on cancer research than the average in Europe. These findings are presented in the Public Library of Science's (PLoS) Medicine pages.

Public funding for cancer research – from governments, charities, and European organisations – is crucially important to reducing the cancer burden, according to the survey's authors, Seth Eckhouse of the European Cancer Research Managers Forum and Richard Sullivan of Cancer Research UK.

They say this funding, focused on the needs of patients with cancer rather than commercial or economic advantage, is essential to delivering the myriad solutions that cancer demands, from new strategies for preventing it, to therapies and improvements in patients' quality of life.

Cancer is one of the biggest ‘disease burdens' and killers in the EU and internationally. With the ageing population and the continuing impact of tobacco-associated cancers, it is predicted that cancer rates could increase by 50% to 15 million new cases worldwide in the year 2020, note the authors.

The latest figures by the International Agency for Research on Cancer estimate close to 2.9 million new cases of cancer diagnosed in 2004 and over 1.7 million cancer deaths. This is despite substantial progress through public health measures (i.e. tobacco control) and new treatments.

“These figures speak for themselves in making the case for a substantial and sustained European approach to cancer through public health measures and research,” the authors note in PLoS. “Europe needs both a strong commercial and a publicly funded (non-commercial) research base.”

Public funding for public quality of life
The study recognises the important contribution that governments, charities and European organisations, such as the EU, make towards funding the “broad church” of research to find new ways to control and cure cancer.

The study identified 139 non-commercial funding organisations that collectively spent €1.43 billion on cancer research from 2002-2003, but with wide variations across the EU, ranging from €388 million in the UK to nothing in Malta. Three EU countries spent more than €100 million, nine greater than €10 million, and ten less than €1 million. Of all the countries in the survey, only Bulgaria failed to report its spending, the authors note.

Compared to the USA, the EU spends more on cancer biology (41% of EU cancer funding versus 25% in the USA). But the United States spends a greater proportion of its available funds on research into prevention (9% in the USA versus 4% in the EU) and treatment (25% versus 20%). In terms of annual budgets in 2002-2003, the US National Cancer Institute spent €3.60 billion, compared with EU spending of €1.43 billion.

The survey also compares spending on cancer research by charities versus that of governments. “Our survey showed that just over 50% of non-commercial funding in the EU (including EFTA and associate states) is provided by the charitable sector, with 65 major charities across 23 countries contributing around €667.3 million to cancer research,” they note.

PLoS

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Article on-line
PloS Medicine (open access on-line scientific journal)

  Top   Research Information Center